在波士顿举行的美国风湿病学会科学年会上公布了这一研究结果。
The findings were presented at the American College of Rheumatology's Annual Scientific Meeting in Boston.
风湿病学家为了这些情况会依靠美国风湿病学会来集中这些专家意见。
Rheumatologists rely on the ACR to gather expert opinion for these situations.
美国风湿病学会的问题是要求进行提议，然后等研究小组的回应，需要一个时间过程。
The ACR issues requests for proposals and then waits for research groups to respond, a process that takes time.
这些事实使得美国风湿病学会在风湿病学监护标准的决定中扮演主要角色显得特别关键。
These facts make it particularly critical for the ACR to play a major role in determining rheumatologic standards of care, Dr. Saag said.
但是那些观点和标记包含在美国风湿病学会的方法里，包括伴随基于推荐方案的专家意见。
But those involved in the ACR's process defended including expert opinion alongside evidence-based recommendations.
所谓“有反应”，是指根据美国风湿病学会关于JIA疗效参数中30%以上有改善且前七天内无发烧症状。
Response was defined as at least 30 percent improvement in the American College of Rheumatology's JIA efficacy variables, along with absence of fever in the preceding seven days.
根据年美国风湿病学会2008年年会上发表的研究结果，它在与其它治疗合用时也可以降低缺血性溃疡的发病率。
It also decreased the incidence of ischemic ulcers when used with other treatments, according to research presented here at the American College of Rheumatology 2008 Annual Scientific Meeting.
依照美国风湿病学会(ARA) 1987年修订的类风湿性关节炎(RA)诊断标准，收集了住院RA34例。
According to the American Rheumatic Association (ARA) 1987 revised criteria for rheumatoid arthritis (RA) 34 admitted patients with RA were collected.
这十年美国风湿病学会(acr)与欧洲风湿病防治联合会(EULAR)公布大纲的步伐比较：从2003年12月以来公布的12个推荐方案。
The pace with which ACR released guidelines earlier this decade contrasts with that of the European League Against Rheumatism (EULAR) : 12 recommendation sets released since December 2003.
这也是真正的美国风湿病学会标准的50%的反应率（27.2%对2.0%）。另外，11.7%的他克莫司治疗组病人获得了美国风湿病学会标准的70%的反应率，而咪唑立宾组无一达到。
This was also true of the ACR50 response (27.2% versus 2.0%). In addition, 11.7% of the tacrolimus patients had an ACR70 response compared with none of the mizoribine patients.
这也是真正的美国风湿病学会标准的50%的反应率（27.2%对2.0%）。另外，11.7%的他克莫司治疗组病人获得了美国风湿病学会标准的70%的反应率，而咪唑立宾组无一达到。
This was also true of the ACR50 response (27.2% versus 2.0%). In addition, 11.7% of the tacrolimus patients had an ACR70 response compared with none of the mizoribine patients.
应用推荐